2 g/10 ml oral solution
GLP-1RA therapy, when prolonged and potent, may lead to a form of iatrogenic ERM : Short-term gains: lower glucose, lower weight, lower cardiovascular risk Long-term risks: impaired amino-acid balance, reduced re-anabolism, muscle loss, frailty, diminished resilience This progression can be subtle and clinically silentbiochemically detectable long before symptoms appear
In contrast, -aminoxy acids, possessing an additional carbon atom compared to -aminoxy acids, exhibit more flexible structures due to the diversity of backbone extensions and substitution possibilities
Most patients begin to notice changes in body composition, energy, or recovery within 46 weeks, though optimal results are typically seen after 812 weeks of consistent use, alongside healthy lifestyle habits
doi: 10.1053/j.semperi.2016.09.007, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar] 56.Takenouchi T, Sugiura Y, Morikawa T, Nakanishi T, Nagahata Y, Sugioka T, et al
1La molcula: semaglutida (semaglutide), quin es, qu hace y por qu importa La semaglutida es un anlogo acilado del pptido similar al glucagn tipo 1 (GLP-1) humano con un 94% de homologa con el GLP-1 endgeno
